{'fraction_non_alphanumeric': 0.063922942206655, 'fraction_numerical': 0.05253940455341506, 'mean_word_length': 5.606936416184971, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Sandwich Radioimmunometric Assay with Murine Monoclonal Antibody, NCC‐ST‐439, for Serological Diagnosis of Human Cancers

Sandwich radioimmunometric assay (RIA) for a new tumor‐associated carbohydrate antigen defined by a monoclonal antibody (MoAb), NCC‐ST‐439, was developed and the antigen levels were determined in sera of normal donors, and patients with various malignant and non‐malignant disorders. In normal donors, 97.0% (226/233) of sera were antigen‐negative (less than 12 units/ml) except for 7 serum samples from young females. In patients with malignant disorders, 34.2% (82/240) were antigen‐positive, in particular 64.0% (16/25) of patients with pancreatic carcinoma, 66.7% (16/24) of patients with recurrent colorectal carcinoma and 54,5% (6/11) of patients with recurrent breast carcinoma. In patients with non‐malignant disorders, 6.0% (7/116) were antigen‐positive. The positive rate in benign hepatobiliary disorders, including gallstones, hepatitis and liver cirrhosis, was especially low at 4.3% (1/23). We concluded that determination of serum NCC‐ST‐439 antigen would be useful in serodiagnosis of carcinoma patients.